Open AccessCleavage‐Responsive Biofactory T Cells Suppress Infectious Diseases‐Associated Hypercytokinemia (Adv. Sci. 26/2022)
Author(s) -
Kim Hyelim,
Son Boram,
Seo Eun U,
Kwon Miji,
Ahn June Hong,
Shin Heungsoo,
Song Gyu Yong,
Park Eun Ji,
Na Dong Hee,
Cho SeungWoo,
Kim Hong Nam,
Park Hee Ho,
Lee Wonhwa
Publication year - 2022
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202270168
Subject(s) - cleavage (geology) , tumor necrosis factor alpha , chemistry , microbiology and biotechnology , cancer research , materials science , medicine , immunology , biology , fracture (geology) , composite material
Engineered T Cells In article number 2201883, Hong Nam Kim, Hee Ho Park, Wonhwa Lee, and co‐workers present chimeric T cells stably expressing therapeutic peptides for treatment of severe infectious diseases. Using lentiviral system, T cells are engineered to express multi‐level therapeutic peptides with matrix metallopeptidases‐ and tumor necrosis factor alpha converting enzyme‐responsive cleavage sites on the surface.